The world may be closer to knowing why Ebola spreads so easily thanks to a team of researchers from Tulane University and other leading institutions who discovered a new biological activity in a small protein from the deadly virus. The team's findings were recently published in the Journal of Virology.
William Wimley is the George A. Adrouny Professor of Biochemistry and Molecular Biology at Tulane University School of Medicine. Courtesy of Guillermo Cabrera-Rojo
The world may be closer to knowing why Ebola spreads so easily thanks to a team of researchers from Tulane University and other leading institutions who discovered a new biological activity in a small protein from the deadly virus. The team's findings were recently published in the Journal of Virology.
The discovery comes as health workers try to contain another Ebola outbreak in a remote area of the Democratic Republic of the Congo. Ebola, which is highly fatal, causes severe vomiting, internal bleeding and extreme gastrointestinal distress.
A compound known as the "delta peptide" is produced in large amounts in Ebola virus-infected patients, but its function isn't yet known. The investigators tested the effects of purified delta peptide on cells from humans and other mammals and found that it could be a viroporin, a type of viral protein that damages host cells by making the membranes become permeable.
"Our leading hypothesis is that the delta peptide affects the gastrointestinal tract by damaging cells after its release from infected cells," says William Wimley, the George A. Adrouny Professor of Biochemistry and Molecular Biology at Tulane University School of Medicine. "This effect may be a major contributor to the severe GI illness of patients with the Ebola virus."
During the West African Ebola that began in late 2013, the virus spread rapidly principally because of the presence of the virus in GI fluids. The lack of effective countermeasures led to the death of more than 11,000 people.
Tulane researchers say the immediate next step is to begin developing therapies that target the delta peptide.
The research involved laboratories from Tulane University School of Medicine, which participated in the fight against Ebola virus on the front lines in Sierra Leone during the outbreak, as well as researchers from Johns Hopkins University and the Louisiana State University Health Sciences Center.
Source: Tulane University
Unmasking Long COVID: Dr Noah Greenspan on Recovery, Research Gaps, and the Future of Treatment
March 18th 2025Dr Noah Greenspan discusses the evolving understanding of long COVID, current treatment strategies, diagnostic challenges, and the critical need for research and awareness in post-viral syndromes.
Obituary: In Memory of SMART4TB and Project ACCELERATE
March 14th 2025In this remembrance of SMART4TB and Project ACCLERATE, 2 global health initiatives, Heather Stoltzfus, MPH, RN, CIC, explains what they are and why they serve as a warning of what has been lost and what more could be lost in the future.
The Art of Wise Leadership in Infection Control and Quality Management
March 14th 2025Discover how wise leadership in infection control transforms challenges into opportunities, fosters teamwork, and safeguards patient safety through emotional intelligence, strategic vision, and inspiring action.
The CDC at a Crossroads: Budget Cuts, Public Health, and the Growing Threat of Infectious Diseases
March 12th 2025Budget cuts to the CDC threaten disease surveillance, outbreak response, and public health programs, increasing risks from measles, avian flu, and future pandemics while straining health care infrastructure nationwide.